These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 5561247)

  • 21. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland.
    Dorgan JF; Albanes D; Virtamo J; Heinonen OP; Chandler DW; Galmarini M; McShane LM; Barrett MJ; Tangrea J; Taylor PR
    Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1069-74. PubMed ID: 9865423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet adhesiveness and lipoprotein lipase activity in patients with benign and malignant disease of the prostate.
    Ham JM; Jones M; Kemp D
    Br J Surg; 1972 Jan; 59(1):60-2. PubMed ID: 5007673
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy.
    Shalev M; Thompson TC; Frolov A; Lippman SM; Hong WK; Fritsche H; Kadmon D
    Clin Cancer Res; 2000 Oct; 6(10):3845-9. PubMed ID: 11051228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of the relations between estrogenic hormones and ceruloplasminemia. An unusual clinical situation: Turner's syndrome].
    Brusa L; Cravario A; De Filippi PG; Cravetto CA
    Folia Endocrinol; 1966 Aug; 19(4):436-51. PubMed ID: 6014455
    [No Abstract]   [Full Text] [Related]  

  • 26. [Serum testosterone level in patients with advanced prostatic cancer during androgen suppressive treatment].
    Fosså SD; Høst H; Aakvaag A
    Tidsskr Nor Laegeforen; 1981 Oct; 101(28):1570-3. PubMed ID: 7339933
    [No Abstract]   [Full Text] [Related]  

  • 27. Factors influencing serum ceruloplasmin levels in normal individuals.
    Cox DW
    J Lab Clin Med; 1966 Dec; 68(6):893-904. PubMed ID: 5926186
    [No Abstract]   [Full Text] [Related]  

  • 28. [Fibrinolysis in prostate carcinomas of varying grades of differentiation with respect to estrogen therapy and castration].
    Oehler D; Feustel A
    Z Urol Nephrol; 1980 Mar; 73(3):201-10. PubMed ID: 7434984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease.
    McArdle PA; McMillan DC; Sattar N; Wallace AM; Underwood MA
    Br J Cancer; 2004 Nov; 91(10):1755-7. PubMed ID: 15505624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of estrogens in development of prostate cancer.
    Härkönen PL; Mäkelä SI
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):297-305. PubMed ID: 15663993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
    Shannon BA; Cohen RJ; Garrett KL
    BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Serum transferrin (STR) and ceruloplasmin (CER) levels studied with the immunological method in patients with malignant neoplasms exposed to radiotherapy].
    Motta R; Brusori G; Vacca G
    Minerva Med; 1966 Aug; 57(67):2767-70. PubMed ID: 4958402
    [No Abstract]   [Full Text] [Related]  

  • 35. [Test of stimulation of ceruloplasmin activity and copper concentration as affected by diphenylhydantoin (phenytoin, TSC) in the diagnosis of hepatolenticular degeneration].
    Pakszys W; Ligezińska B; Szymański H
    Pol Tyg Lek; 1982 Nov; 37(45):1353-7. PubMed ID: 7163091
    [No Abstract]   [Full Text] [Related]  

  • 36. [Changes of serum protein before and after operation in patients with prostatic diseases].
    Kazuta M; Fujimoto Y; Ogawa M; Ishibe T
    Hinyokika Kiyo; 1967 Jan; 13(1):23-9. PubMed ID: 5624256
    [No Abstract]   [Full Text] [Related]  

  • 37. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Calcium, phosphorus, copper, creatinine and ceruloplasmin content in the blood of workers in contact with carbon disulfide].
    Pavlova S
    Probl Khig; 1980; 5():116-23. PubMed ID: 7443651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum copper, ceruloplasmin and thiobarbituric acid reactive substance status in patients with ovarian cancer.
    Nayak SB; Bhat VR; Mayya SS
    Indian J Physiol Pharmacol; 2004 Oct; 48(4):486-8. PubMed ID: 15907060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Quantitative evaluation of ceruloplasmin in different skin diseases].
    Caccialanza P; Finzi AF
    G Ital Dermatol Minerva Dermatol; 1966; 107(5):563-70. PubMed ID: 6014658
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.